Last 44 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -68.32 | 13.38 | 490.69 | — | — | — | — | 4.87 | — | — | 2.22 | 13.03 | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | -62.6% | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 195.75 | 10.19 | 32.95 | 186.65 | 224.77 | 158.23 | 26.88 | 3.76 | 148.64 | 127.44 | 1.80 | 5.90 | — | — | — | — | — | 112.92 | 11.22 | 47.78 | 20.67 |
| — | -93.6% | +22.6% | +4870.1% | +51.2% | +24.2% | +1389.9% | -36.4% | — | — | — | — | — | — | — | — | — | -49.2% | -75.7% | +35.2% | +48.3% | |
| P/B Ratio | 14.48 | 10.34 | 11.34 | 9.03 | 6.56 | 5.25 | 4.42 | 3.80 | 5.23 | 3.92 | 3.28 | 4.21 | 3.27 | 5.33 | 5.38 | 2.49 | 1.70 | 1.45 | 3.83 | 5.49 | 2.58 |
| — | +96.8% | +156.5% | +138.0% | +25.6% | +33.9% | +34.6% | -9.8% | +59.9% | -26.4% | -39.0% | +68.8% | +92.3% | +268.3% | +40.7% | -54.6% | -34.1% | -74.3% | -13.4% | +92.2% | -40.2% | |
| P/FCF | 160.62 | 12.82 | — | — | — | — | 6.10 | — | — | 1.98 | — | 20.91 | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | 12.56 | — | — | — | — | — | 4.86 | — | — | 2.02 | 12.89 | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | -62.3% | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | 12.56 | 794.17 | — | — | — | — | 4.63 | — | — | 1.98 | 13.36 | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | -65.3% | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 97.3% | 100.0% | 99.3% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | — | — | — | — | — | 1.9% | 96.8% | 90.5% | 100.0% |
| — | 0.0% | -0.7% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — | — | — | — | — | — | -98.1% | -3.2% | -9.5% | 0.0% | |
| Operating Margin | -343.6% | 74.4% | -6.5% | -677.1% | -985.2% | -758.0% | -68.2% | 74.3% | -886.7% | -931.0% | 80.9% | 38.4% | — | — | — | — | — | -4824.6% | -82.1% | -440.0% | -329.8% |
| — | +109.8% | +90.5% | -1011.3% | -11.1% | +18.6% | -184.3% | +93.4% | — | — | — | — | — | — | — | — | — | -253.9% | +78.9% | -32.0% | -456.5% | |
| Net Margin | -282.8% | 76.3% | 6.7% | -596.8% | -834.9% | -627.0% | -41.2% | 77.2% | -710.4% | -734.7% | 81.3% | 45.6% | — | — | — | — | — | -4777.3% | -81.4% | -428.3% | -328.6% |
| — | +112.2% | +116.3% | -873.4% | -17.5% | +14.7% | -150.6% | +69.4% | — | — | — | — | — | — | — | — | — | -250.8% | +79.0% | -28.1% | -455.2% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -20.2% | 21.8% | 0.6% | -7.0% | -6.0% | -5.1% | -1.7% | 21.8% | -6.2% | -5.6% | 46.2% | 8.6% | -11.4% | -15.1% | -15.6% | -14.9% | -12.2% | -14.4% | -7.0% | -11.7% | -9.8% |
| — | +524.6% | +134.9% | -132.3% | +3.2% | +7.8% | -103.7% | +154.9% | +45.9% | +63.1% | +395.9% | +157.5% | +6.3% | -4.7% | -124.6% | -27.0% | -24.1% | -44.0% | +21.9% | -39.4% | -113.6% | |
| ROA | -18.4% | 20.6% | 0.6% | -6.5% | -5.5% | -4.8% | -1.6% | 19.5% | -5.5% | -4.9% | 42.0% | 7.9% | -10.5% | -13.7% | -13.8% | -12.9% | -10.5% | -12.5% | -6.0% | -10.2% | -8.7% |
| — | +532.0% | +135.3% | -133.1% | -1.7% | +3.2% | -103.7% | +145.7% | +48.0% | +64.1% | +403.8% | +161.6% | +0.5% | -10.2% | -129.9% | -26.0% | -21.2% | -41.8% | +22.0% | -46.9% | -147.7% | |
| ROIC | -21.8% | 26.4% | -0.6% | -7.3% | -6.6% | -5.9% | -2.5% | 19.0% | -10.2% | -9.9% | 57.4% | 15.4% | -42.7% | -41.6% | -29.2% | -29.0% | -19.6% | -17.2% | -8.1% | -14.3% | -13.2% |
| — | +548.5% | +77.6% | -138.2% | +35.3% | +40.8% | -104.4% | +23.4% | +76.1% | +76.1% | +296.5% | +153.0% | -118.3% | -141.8% | -260.4% | -103.1% | -48.3% | -30.9% | +21.3% | -31.9% | -35.9% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.02 | 0.01 | 0.01 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 |
| — | -35.1% | -9.5% | +4.4% | -18.7% | -16.7% | +1900.7% | +374.8% | +243.4% | +143.7% | -94.2% | -80.0% | -65.7% | -53.5% | -19.9% | -13.2% | -8.5% | +21.7% | -18.3% | -8.4% | -48.8% | |
| Debt / EBITDA | — | 0.06 | — | — | — | — | — | 0.09 | — | — | 0.00 | 0.05 | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | +78.6% | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 12.71 | 21.71 | 17.76 | 12.71 | 13.05 | 16.97 | 17.26 | 12.48 | 10.70 | 13.73 | 15.72 | 16.71 | 11.66 | 12.01 | 10.15 | 7.80 | 7.53 | 7.59 | 7.86 | 7.74 | 8.37 |
| — | +27.9% | +2.9% | +1.8% | +22.0% | +23.6% | +9.7% | -25.3% | -8.3% | +14.4% | +54.9% | +114.4% | +54.9% | +58.2% | +29.1% | +0.7% | -10.1% | -12.3% | -5.0% | -1.3% | +58.1% | |
| Quick Ratio | 12.71 | 21.71 | 17.76 | 12.71 | 13.05 | 16.97 | 17.26 | 12.48 | 10.70 | 13.73 | 15.72 | 16.71 | 11.66 | 12.01 | 10.15 | 7.80 | 7.53 | 7.59 | 7.86 | 7.74 | 8.37 |
| — | +27.9% | +2.9% | +1.8% | +22.0% | +23.6% | +9.7% | -25.3% | -8.3% | +14.4% | +54.9% | +114.4% | +54.9% | +58.2% | +29.1% | +0.7% | -10.1% | -12.3% | -5.0% | -1.3% | +58.1% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 44 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying PTGX stock.
Protagonist Therapeutics, Inc.'s current P/E is -68.3x. The average P/E over the last 2 quarters is 252.0x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Protagonist Therapeutics, Inc.'s current operating margin is -343.6%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Protagonist Therapeutics, Inc.'s business trajectory between earnings reports.